BrainsWay Receives FDA Approval for ProlivRx to Treat Major Depressive Disorder
BrainsWay announced that the U.S. Food and Drug Administration, FDA, has granted Premarket Approval, PMA, for Neurolief's ProlivRx system, a Class III device, as an adjunctive treatment for adult patients suffering from major depressive disorder, MDD, who have failed to achieve satisfactory improvement from at least one previous antidepressant medication, for use at home or in the clinic. This approval represents a significant regulatory milestone, making ProlivRx the first and only at-home neuromodulation treatment with FDA labeling applicable to treatment refractory MDD patients.
Trade with 70% Backtested Accuracy
Analyst Views on BRN
About BRN
About the author
Barnwell Revenue Drops 29% in Fiscal Q3
Financial Performance: Barnwell Industries reported a significant decline in Q3 2025, with revenue dropping 29.2% to $3.19 million and a net loss of $1.55 million due to increased legal and administrative expenses.
Strategic Shift: The company has sold all U.S. oil and gas assets for $2.3 million, marking a complete retreat from the U.S. market and focusing future operations on Canadian energy activities, while facing ongoing liquidity risks and uncertainty about its financial viability.
Barnwell Industries Inc. Q3 Loss Widens
Financial Performance: Barnwell Industries Inc. reported a third-quarter loss of -$1.550 million, or -$0.15 per share, compared to a loss of -$1.246 million, or -$0.12 per share, in the previous year, with revenue declining by 29.2% to $3.192 million.
CEO's Statement: CEO Craig D. Hopkins highlighted the sale of U.S. oil and natural gas properties as a means to fund well workovers and address production declines, while also indicating the need for additional capital to develop assets at Twining and manage ongoing shareholder disputes.